SEARCH RESULTS

27 RESULTS

John Breitner on Merck Withdraws Vioxx®

COMMENT Alzforum subscribers have no doubt heard that Merck has withdrawn its blockbuster COX-2 inhibitor Vioxx (rofecoxib) from the market because of increased risks of heart attack and stroke. Most are aware also that the COX-2 inhibitors, including Celebrex ...

John Breitner on Naproxen/Rofecoxib Trial Results Published

COMMENT This is the fifth published trial of antiinflammatory treatments for disease modification or symptomatic improvement in Alzheimer's dementia. Two early small studies showed an encouraging suggestion of disease modification (slowing or progression) in ...

Current Filters

  • TYPE: Comment x
  • Commentator: Breitner, John x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE